Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Kraleva, Slavica

Search Results

Now showing 1 - 4 of 4
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    HER2/neu expression in correlation with p53 and Ki-67 immunoreactivity and clinicopathological parameters in breast cancer patients.
    (Blackwell Publishing, 2002-10)
    Yashar, Genghis
    ;
    ;
    Ivkovski, Ljube
    ;
    Kraleva, Slavica
    ;
    Prodanova, Irina
    Introduction: Although the role of HER2/neu status is still unsettled, its determination is valuable in selecting breast carcinoma patients for adequate Herceptin therapy. Aims: The purpose of this study was to evaluate the association among HER2/neu, p53 and Ki-67 immunoreactivity, as well as clinicopathological parameters (tumour size, histopathologic grade, nuclear grade, tumour type. lymph-node status and age) in breast cancer patients. Materials and methods: HER2/neu, p53 and Ki-67 expression was determined in 169 post-operative stage I-III (UICC. 1997) breast cancer patients using the standardized DAKO HercepsTest and by immunoperoxidase technique. respectively. The results were evaluated by performing the standardized scoring system. Discussion and conclusion: HER2/neu expression was positive in 66 patients (37%). There was no association between HER2/neu expression and p53 or Ki-67 immunoreactivity as well as any clinicopathological parameter, while the values of Ki-67 and p53 were strongly interrelated (P < 0.001). Ki-67 was also in significant correlation to tumour size, lymph-node involvement and tumour type (P<0.001), while p53 was only related to patients' age (P <0.01). These results indicate that HER2/neu is an independent prognostic marker in differentiating a subgroup of high-risk breast cancer patients. Additional studies are required to adjust HER2/neu testing results to clinical outcome.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Association between Her2/neu expression and hormon receptor status in breast cancer patients.
    (2002-06)
    Yashar, Genghis
    ;
    ;
    Kraleva, Slavica
    ;
    Vasev, Nikola
    ;
    Ivkovski, Ljube
    Determination of HER2/neu expression by immunohistochemistry is mandatory for application of Herceptin® therapy in breast cancer patients. The purpose of this study was to investigate the association between HER2/neu expression and hormone receptor status, as well as with other clinicopathological parameters in breast cancer patients. HER2/neu, p53 and Ki-67 expression was determined in 169 postoperative stage I-III (UICC, 1997) breast cancer patients using the standardized DAKO HercepsTest® and immunoperoxidase technique, respectively. The results of HER2/neu immunoreactivity were evaluated by performing the standardized scoring system (0 = negative, 1+ = weakly positive, 2+ = positive, 3+ = strongly positive staining), while ER and PgR were scored in a semiquantitative fashion (ER-ICA and PR-ICA). The results from HER2/neu expression were correlated to hormonal receptor status and clinicopathological parameters (tumor size, histopathologic grade, nuclear grade, histologic type of the tumor, lymph node status and patient age). Statistical significance was determined with χ2 and Fisher’s exact test. HER2/neu expression was positive in 66 patients (37%). There was no significant association between the values of HER2/neu and ER/PgR status, or with any other clinicopathological parameter. ER status significantly correlated with PgR status (p<0.01), tumor size (p<0.01), lymph-node involvement (p<0.01) and tumor type (p<0.01). PgR status was related to the histopathologic grade (p<0.01), lymph-node status (p<0.01), tumor type (p<0.01) and patient age (p<0.01). HER2/neu is a relatively new promising marker in predicting the response to target specific therapy. However, its predictive value remains a complex and inconclusive subject. According to our results, the prognostic potential of HER2/neu seems to be independent from hormone receptor status and any other clinicopathological parameter in breast cancer patients.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Her2/neu expression in breast cancer patients - Correlation with estrogen and progesterone receptor status, p53 and Ki-67 immunoreactivity and clinicopathological parameters
    (Institute of Oncology, Sremska Kamenica, Yugoslavia, 2002-09)
    Yashar, Genghis
    ;
    ;
    Prodanova, Irina
    ;
    Vasev, Nikola
    ;
    Kraleva, Slavica
    Although the role of HER2/neu status is still unsettled, its determination is valuable in selecting breast carcinoma patients for adequate Herceptin¨ therapy. The purpose of this study was to investigate the association between HER2/neu expression with estrogen (ER) and progesterone (PgR) receptor status, p53 and Ki-67 immunoreactivity, as well as with other clinicopathological parameters in breast cancer patients. HER2/neu, ER/PgR status, p53 and Ki-67 expression was determined in 169 postoperative stage I-III (UICC, 1997) breast cancer patients using the standardized DAKO HercepsTest¨ and by the immunoperoxidase technique, respectively. The results were evaluated by performing the standardized scoring system. The values of HER2/neu expression were correlated to ER/PgR status, p53 and Ki-67 immunoreactivity and to clinicopathological parameters (tumor size, histopathologic grade, nuclear grade, tumor type, and lymph node status and patients’ age). The statistical significance was determined with c2 and Fisher’s exact test. HER2/neu expression was positive in 66 patients (37%). There was no significant association between the values of HER2/neu and ER/PgR status, p53 or Ki-67 immunoreactivity, neither with any other clinicopathological parameter. ER is associated with PgR, tumor size, tumor type and lymph node status (p<0.01); PgR with histopathologic grade, tumor type and lymph node status (p<0.01) and Ki-67 with p53 immunoreactivity, tumor size and patients’ age (p<0.01). The results of the current study indicate that HER2/neu is an independent prognostic marker in differentiating a subgroup of high-risk breast cancer patients. Additional studies are required to adjust HER2/neu testing results to the clinical outcome.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Use of analgesics in patients affected by head & neck malignancy during palliative radiotherapy
    (2003)
    ;
    ;
    Kraleva, Slavica
    ;
    ;
    Stojmenova, Vita
    Background: Treating the Head & Neck malignancy failure after surgery and radiotherapy (RT) is still a problem. The roles of reirradiation and chemotherapy are palliative. These patients (pts) suffered from moderate to sever pain that was less responsive to opioid therapy. The aim of this study was to evaluate efficiency among tramadol and amitriptyline in head & neck cancer pts with moderate pain during palliative RT. Material and Methods: 30 pts (21 M, 9 F) affected by head & neck metastatic disease in lymph nodes, failure after primary therapy. All pts included presented moderate pain defined as VAS between 5–7, and were under NSAIDs treatment and palliative RT. 15 pts (group A) used tramadol with initial dose 200 mg/day, with doses escalated up to 300-400/day. Other 15 pts (group B) used amitriptyline with starting dose 10 mg in the elderly and 25 mg in younger pts with doses increased every few days, when doses have reached the effective range (e.g. 75–100 mg). Pain was measured according the linear VAS (0-10) at the start of and during the period and at the end of RT, including day 0, 7, 14 and 21. Results: There was a difference between groups in VAS evaluation, this was: 6.2, 5.3, 4.8, 4.9 at days 0, 7, 14, and 21 respectively for tramadol group-A and 6.1, 3.5, 1.7, 1.2, respectively for group-B. Percentage of pts under pain control (VAS <3) was registered only in group B in follow up visits (40.6% at day 7, 80% at day 14 and 86.6 % at day 21). Conclusions: Tricyclic antidepressant-amitripyline was significant efficiency pain treatment in head & neck cancer pts with moderated pain. Considering our results, we supposed that there is distinct mechanism that created neuropathic pain in the head & neck region. available by spring 2003. 74P